Company Description

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.

It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.

The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus, Inc.

Country	United States
Founded	2012
IPO Date	Feb 8, 2018
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	334
CEO	David Moatazedi

Contact Details

Address: 520 Newport Center Drive, Suite 1200 Newport Beach, California 92660 United States
Phone	949 284 4555
Website	evolus.com

Stock Details

Ticker Symbol	EOLS
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001570562
CUSIP Number	30052C107
ISIN Number	US30052C1071
Employer ID	46-1385614
SIC Code	2834

Key Executives

Name	Position
David Moatazedi	President, Chief Executive Officer and Director

Latest SEC Filings

Date	Type	Title
May 4, 2026	10-Q	Quarterly Report
May 4, 2026	8-K	Current Report
Apr 29, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2026	DEF 14A	Other definitive proxy statements
Apr 29, 2026	ARS	Filing
Mar 26, 2026	SCHEDULE 13G/A	Filing
Mar 13, 2026	8-K	Current Report
Mar 3, 2026	S-8	Securities to be offered to employees in employee benefit plans
Mar 3, 2026	10-K	Annual Report
Mar 3, 2026	8-K	Current Report

View All SEC Filings